<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN"
        "https://jats.nlm.nih.gov/publishing/1.4/JATS-journalpublishing1-4.dtd">
<article  article-type="research-article"        dtd-version="1.4">
            <front>

                <journal-meta>
                                                                <journal-id>j. res. pharm.</journal-id>
            <journal-title-group>
                                                                                    <journal-title>Journal of Research in Pharmacy</journal-title>
            </journal-title-group>
                                        <issn pub-type="epub">2630-6344</issn>
                                                                                            <publisher>
                    <publisher-name>Marmara University</publisher-name>
                </publisher>
                    </journal-meta>
                <article-meta>
                                        <article-id pub-id-type="doi">10.35333/jrp.2020.204</article-id>
                                                                <article-categories>
                                            <subj-group  xml:lang="en">
                                                            <subject>Pharmacology and Pharmaceutical Sciences (Other)</subject>
                                                    </subj-group>
                                            <subj-group  xml:lang="tr">
                                                            <subject>Eczacılık ve İlaç Bilimleri (Diğer)</subject>
                                                    </subj-group>
                                    </article-categories>
                                                                                                                                                        <title-group>
                                                                                                                                                            <article-title>Formulation and evaluation of fluvastatin sodium drugin-adhesive transdermal system</article-title>
                                                                                                    </title-group>
            
                                                    <contrib-group content-type="authors">
                                                                        <contrib contrib-type="author">
                                                                <name>
                                    <surname>Geevarghese</surname>
                                    <given-names>Rachel</given-names>
                                </name>
                                                                    <aff>Department of Pharmaceutics, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Shirolkar</surname>
                                    <given-names>Satish</given-names>
                                </name>
                                                                    <aff>Department Of Pharmaceutics, Dr. D.y. Patil Institute Of Pharmaceutical Sciences And Research</aff>
                                                            </contrib>
                                                                                </contrib-group>
                        
                                        <pub-date pub-type="pub" iso-8601-date="20250627">
                    <day>06</day>
                    <month>27</month>
                    <year>2025</year>
                </pub-date>
                                        <volume>24</volume>
                                        <issue>4</issue>
                                        <fpage>562</fpage>
                                        <lpage>571</lpage>
                        
                        <history>
                                    <date date-type="received" iso-8601-date="20191008">
                        <day>10</day>
                        <month>08</month>
                        <year>2019</year>
                    </date>
                                                    <date date-type="accepted" iso-8601-date="20200330">
                        <day>03</day>
                        <month>30</month>
                        <year>2020</year>
                    </date>
                            </history>
                                        <permissions>
                    <copyright-statement>Copyright © 2010, Journal of Research in Pharmacy</copyright-statement>
                    <copyright-year>2010</copyright-year>
                    <copyright-holder>Journal of Research in Pharmacy</copyright-holder>
                </permissions>
            
                                                                                                                        <abstract><p>Current investigation is aimed at designing a fluvastatin sodium loaded drug-in-adhesive patch (DIA Patch ) to overcome the problems associated with the daily oral administration of the drug. The patches were prepared by solvent casting method using acrylate emulsion polymers like covinax 525-78, mowinyl 461 and novacryl PSR32 which served as sustained release matrix polymer and adhesive. Methocel K-15M was added as a solubilizer whereas transcutol, oleic acid and isopropyl myristate were tried as permeation enhancers for the drug-in-adhesive patch. The combination of mowinyl-isopropyl myristate patch was further optimized by 32 factorial design to study the effect of two independent variables i.e. concentration of solubilizer and permeation enhancer on responses i.e.% drug release, tensile strength and peel adhesion strength. The formulation was further evaluated for its lipid lowering activity and skin irritation index. The % cumulative release of drug at the end of 24 h was found to be 87.74%. The formulation shows tensile strength of 12.75 kg/cm2 and peel adhesion strength of 32.44 N/25 mm. The Primary irritation index (PII) for DIA patch was found to be 0.22. The fluvastatin sodium loaded DIA patch significantly inhibits serum cholesterol and triglyceride levels as compared to oral control (p&amp;lt;0.01) in triton WR 1339 induced hyperlipidemic rat. Hence the developed transdermal patch could be acceptable for transdermal use.</p></abstract>
                                                            
            
                                                                                        <kwd-group>
                                                    <kwd>Pressure-sensitive–adhesive</kwd>
                                                    <kwd>  fluvastatin sodium</kwd>
                                                    <kwd>  drug-in-adhesive patch</kwd>
                                                    <kwd>  % cumulative release</kwd>
                                                    <kwd>  peel
adhesion strength</kwd>
                                                    <kwd>  total cholesterol</kwd>
                                            </kwd-group>
                            
                                                                                                                                                    </article-meta>
    </front>
    <back>
                            <ref-list>
                                    <ref id="ref1">
                        <label>1</label>
                        <mixed-citation publication-type="journal">[1] Pastore M , Kalia Y, Horstmann M , Roberts M. Transdermal patches : history, development and pharmacology. Br J Pharmacol. 2015; 172(9): 2179–2209. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref2">
                        <label>2</label>
                        <mixed-citation publication-type="journal">[2] Al Hanbali O, Khan H, Sarfra M, Arafat M, Ijaz S, Hameed A.Transdermal patches: design and current approaches to painless drug delivery. Acta Pharma. 2019; 69(2): 197–215. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref3">
                        <label>3</label>
                        <mixed-citation publication-type="journal">[3] Schechter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005; 19: 117-125. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref4">
                        <label>4</label>
                        <mixed-citation publication-type="journal">[4] Puri A, Bhattaccharjee S, Zhang W, Clark M, Singh O, Doncel G, Banga A. Development of a transdermal delivery system for tenofovir alafenamide, a prodrug of tenofovir with potent antiviral activity against HIV and HBV. Pharmaceutics. 2019; 11(173): 1-29. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref5">
                        <label>5</label>
                        <mixed-citation publication-type="journal">[5] Regenthal R, Voskanian M, Baumann F ,Teichert J, Brätter C, Aigner A, Abraham G. Pharmacokinetic evaluation of a transdermal anastrozole-in-adhesive formulation. Drug Des Devel Ther. 2018; 12: 3653-3664. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref6">
                        <label>6</label>
                        <mixed-citation publication-type="journal">[6] Siafaka P, Barmpalexis P,Lazaridou M ,Papageorgiou G, Koutris E, Karavas E, Kostoglou M, Bikiaris D.Controlled release formulations of risperidone antipsychotic drug in novel aliphatic polyester carriers:data analysis and modelling. Eur J Pharm Biopharm. 2015; 94: 473-484. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref7">
                        <label>7</label>
                        <mixed-citation publication-type="journal">[7] Parhi R, Padilam S .In vitro permeation and stability studies on developed drug-in-adhesive transdermal patch of simvastatin. Bulletin of Faculty of Pharmacy, Cairo University. 2018; 56(1): 26-33. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref8">
                        <label>8</label>
                        <mixed-citation publication-type="journal">[8] Okur N, Filippousi A, Okur M, Ayla S, Caglar E, Yoltas A, Siafaka P. A novel approach for skin infections: controlled release topical mats of poly(lactic acid)/polyethylene succinate blend containiny voriconazole. J Drug Deliv Sci Technol. 2018; 46: 74-86. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref9">
                        <label>9</label>
                        <mixed-citation publication-type="journal">[9] Okur N, Hökenek N, Okur M, Ayla S, Yoltaş A, Siafaka P, Cevher E. An alternative approach to wound healing field; new composite films from natural polymers for mupirocin dermal delivery. Saudi Pharm J. 2019; 27(5): 738-752. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref10">
                        <label>10</label>
                        <mixed-citation publication-type="journal">[10] Jafri I, Shoaib M, Yousuf R, Ali F. Effect of permeation enhancers on in vitro release and transdermal delivery of lamotrigine from Eudragit®RS100 polymer matrix-type drug in adhesive patches. Prog Biomater. 2019; 8(2): 91-100. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref11">
                        <label>11</label>
                        <mixed-citation publication-type="journal">[11] Hsieh L, Box K, Taylor S. Assessing the Impact of polymers on the pH-induced precipitation behaviour of poorly water soluble compounds using synchrotron wide angle X-ray scattering. J Pharm Sci. 2014; 103: 2724–2735. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref12">
                        <label>12</label>
                        <mixed-citation publication-type="journal">[12] Suys J, Chalmers D, Pouton C, Porte C.Polymeric precipitation inhibitors promote fenofibrate supersaturation and enhance drug absorption from a type IV lipid based formulation. Mol Pharm. 2018; 15(6): 2355-2371. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref13">
                        <label>13</label>
                        <mixed-citation publication-type="journal">[13] Hadgraft H, Lane M . Drug crystallization – implications for topical and transdermal delivery. Expert Opin Drug Deliv. 2016; 13(6): 817-830. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref14">
                        <label>14</label>
                        <mixed-citation publication-type="journal">[14] Weng W, Quan P, Liu C, Zhao H, Fang L. Design of a drug-in-adhesive transdermal patch for risperidone: effect of drug-additive interactions on the crystallization inhibition and in vitro/in vivo correlation study. J Pharm Sci. 2016; 105(10): 3153-3161. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref15">
                        <label>15</label>
                        <mixed-citation publication-type="journal">[15] Jain P, Banga AK .Inhibition of crystallization in drug-in-adhesive-type transdermal patches. Int J Pharm. 2010 ; 394 (1-2): 68-74. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref16">
                        <label>16</label>
                        <mixed-citation publication-type="journal">[16] Zhao C, Quan P, Liu C, Li Q, Fang L.Effect of isopropyl myristate on the viscoelasticity and drug release of a drugin-adhesive transdermal patch containing blonanserin. Acta Pharm Sin B. 2016; 6(6): 623–628. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref17">
                        <label>17</label>
                        <mixed-citation publication-type="journal">[17] Schurr P , Schultz J , Parkinson T . Triton-induced hyperlipidemia in rats as an animal model for screening hypolipidemic drugs. Lipids. 1972; 7(1): 68-74. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref18">
                        <label>18</label>
                        <mixed-citation publication-type="journal">[18] Otway S, D. S. Robinson. The use of a non‐ ionic detergent (triton WR 1339) to determine rates of triglyceride entry into the circulation of the rat under different physiological conditions.J Physiol. 1967; 190(2): 321-332. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref19">
                        <label>19</label>
                        <mixed-citation publication-type="journal">[19] Li J, Yang M, Xu W. Enhanced oral bioavailability of fluvastatin by using nanosuspensions containing cyclodextrin. Drug Des Devel Ther. 2018; 12: 3491-3499. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref20">
                        <label>20</label>
                        <mixed-citation publication-type="journal">[20] Sharma P, Panda A, Pradhan A, Zhang J, Thakkar R, Whang C, Repka M, Murthy S. Solid-state stability issues of drugs in transdermal patch formulations. AAPS PharmSciTech. 2017; 19(1): 27-35. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref21">
                        <label>21</label>
                        <mixed-citation publication-type="journal">[21] Geevarghese R, Shirolkar S. RP-HPLC method for estimation of rosuvastatin calcium from bulk and transdermal dosage form. Int J Pharm Sci Res. 2018; 9(11): 4875-4879. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref22">
                        <label>22</label>
                        <mixed-citation publication-type="journal">[22] Lal N, Yadav P ,Rastogi V, Verma A, Verma N . Aspects of pressure sensitive adhesives in fabricating drug-in adhesive transdermal therapeutic systems. Drug Deliv Lett. 2017; 7(1): 3-15. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref23">
                        <label>23</label>
                        <mixed-citation publication-type="journal">[23] Niharika L, Pragya Y, Vaibhav V, Lalit P, Navneet V, AnuragV. Development and evaluation of transdermal therapeutic system of metoprolol succinate using acrylic polymer. Asian J Pharm. 2016; 10(3): 178-187.</mixed-citation>
                    </ref>
                                    <ref id="ref24">
                        <label>24</label>
                        <mixed-citation publication-type="journal">[24] Mendes M, Nunes S, Sousa J, Pais A, Vitorino C. Expanding transdermal delivery with lipid nanoparticles: a new drug-in-NLC-in-adhesive design. Mol Pharm. 2017; 14(6): 2099-2115. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref25">
                        <label>25</label>
                        <mixed-citation publication-type="journal">[25] Anod H, Gupta V, Gowda D, Manohar M. Preparation and evaluation of simvastatin transdermal film. Int. J. Appl. Pharm. 2018; 10(5): 235-238. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref26">
                        <label>26</label>
                        <mixed-citation publication-type="journal">[26] Taghizadeh S, Ardakani A, Mohamadnia F. Statistical experimental design approach to evaluate the influence of various penetration enhancers on transdermal drug delivery of buprenorphine. J Adv Res. 2015; 6: 155–162. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref27">
                        <label>27</label>
                        <mixed-citation publication-type="journal">[27] Wang J, Li Z, Sun F, Tang S, Zhang S, Pengyyue L.Evaluation of dermal irritation and skin sensitization due to vitacoxib. Toxicol Rep . 2017; 4: 287–290. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref28">
                        <label>28</label>
                        <mixed-citation publication-type="journal">[28] Bautista A, Tan M, Apostol J. Lipid-lowering property of Clausena anisum-olens in hypercholesterolemic rats. Pharm Biol. 2017; 55(1): 833-836. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref29">
                        <label>29</label>
                        <mixed-citation publication-type="journal">[29] Surya S, Kurup R, Kumar A, Carla B, Sunil C. Antihyperlipidemic effect of Ficus dalhousiae miq. stem bark on Triton WR-1339 and high fat diet induced hyperlipidemic rats. Bulletin of Faculty of Pharmacy, Cairo University. 2017; 55(1): 73-77. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref30">
                        <label>30</label>
                        <mixed-citation publication-type="journal">[30] Murugaiyah V, Ahmed Saeed M, Kuong Y, Murugesu K, Parasuraman S, Asmawi M, Sadikun A. Lipid lowering effect of hydroalcoholic extracts of Gynura procumbens in chemical and high fat diet induced hyperlipidemic rats. Phcog Mag. 2018; 14(55): 184-191. [CrossRef]</mixed-citation>
                    </ref>
                            </ref-list>
                    </back>
    </article>
